Patent litigation insights on barriers to US biosimilar market growth

Biosimilars/Research | Posted 29/10/2021 post-comment0 Post your comment

High prices of biological drugs have placed substantial strain on the US healthcare system. To help address this problem, Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) as part of the Affordable Care Act, which created an abbreviated approval pathway for biosimilars – versions of ‘originator’ biological drugs made by different manufacturers. To resolve disputes over whether a biosimilar manufacturer would infringe patents on the originator biological by entering the market, the BPCI Act included a multi-step litigation process, which starts when the biosimilar manufacturer submits its abbreviated biological license application to the US Food and Drug Administration (FDA). However, a decade after its passage, the BPCI Act has spurred only limited competition [1].

Patent 1 V13E17

Van de Wiele et al. examined the role that patent litigation has played in this muted success, reviewing all 21 lawsuits related to the BPCI Act filed between its enactment and 1 August 2020 [2]. The review identified two key problems. First, claims of biosimilar manufacturer non-compliance with the BPCI Act litigation process were present in 19 (90%) complaints. These claims included ‘failure to share an [abbreviated biological license application]’ [3, 4], ‘failure to exchange patent lists’ [5] and ‘failure to engage in good faith negotiations’ [6, 7]. Potential reasons for this high proportion include a 2016 Supreme Court decision in Sandoz v Amgen, which limited the consequences of non-compliance [8] and biosimilar manufacturer concerns about sharing sensitive information found in the abbreviated biological license application. Second, a wide range of patents were alleged to be infringed across the 21 cases, with nine cases involving 20 or more patents. Combined, non-compliance with the litigation process and large numbers of litigated patents have contributed to frequent confidential settlements between originator and biosimilar manufacturers, which has delayed the availability of biosimilars.

To facilitate more timely biosimilar entry, Van de Wiele et al. argue that policymakers should consider:
• Re-evaluating the litigation process to become more in line with the litigation process for small-molecule drugs
• Addressing excess patenting by giving patent examiners more time
• Limiting biological patent enforceability, possibly by capping the number of patents that can be obtained or litigated
• Mandating public patent listing for biologicals
• Enhancing anti-trust enforcement of patent settlement agreements

Conflict of interest
The authors of the research paper [2] have declared their funding and conflict of interest in the paper. For full details of the authors’ conflict of interest, see the research paper [2].

Abstracted by Victor L Van de Wiele, LLB, LLM, Research Fellow, Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, USA.

Editor’s comment
Readers interested to learn more about biosimilar patent litigation are invited to visit to view the following manuscripts published in GaBI Journal:

Biosimilars patent litigation in the EU and the US: a comparative strategic overview

Biosimilars patent litigation in Canada and Japan: a comparative strategic overview and EU and US update

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
2.0 – CiteScoreTracker 2021 (Last updated on 5 October 2021)

Submit a manuscript to GaBI Journal

Related articles
Notice can be given before FDA approves biosimilar

US biosimilars law may prove a barrier to entry for biosimilars


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. Sarpatwari A, Barenie R, Curfman G, et al. The US biosimilar market: stunted growth and possible reforms. Clin Pharmacol Ther. 2019;105(1):92-100.
2. Van de Wiele VL, Kesselheim AS, Sarpatwari A. Barriers to US biosimilar market growth: lessons from biosimilar patent litigation. Health Aff. 2021;40(8):1198-205.
3. Amgen v. Sandoz, No. 3:14-cv-04741 (N.D.Cal.) (2015).
4. GaBI Online - Generics and Biosimilars Initiative. US Supreme Court to review 180-day notice for biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 29]. Available from:
5. Genentech Inc. v. Celltrion Inc. No. 1-18-cv-00095 (D.Del.) (2018).
6. Genentech Inc. v. Celltrion Inc. No. 1:18-cv- 11553-RMB-KMW (D.N.J.) (2018).
7. GaBI Online - Generics and Biosimilars Initiative. Biosimilar patent litigation trends in the US []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 29]. Available from:
8. Sarpatwari A, Gluck AR, Curfman G. The Supreme Court ruling in Sandoz v Amgen: a victory for follow-on biologics. JAMA Intern Med. 2018;178(1):5-6.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010